- Retrait gratuit dans votre magasin Club
- 7.000.000 titres dans notre catalogue
- Payer en toute sécurité
- Toujours un magasin près de chez vous
- Retrait gratuit dans votre magasin Club
- 7.000.000 titres dans notre catalogue
- Payer en toute sécurité
- Toujours un magasin près de chez vous
Indacaterol
The First Once-Daily Long-Acting Beta2 Agonist for Copd
105,45 €
+ 210 points
Description
Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled beta2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
Spécifications
Parties prenantes
- Editeur:
Contenu
- Nombre de pages :
- 146
- Langue:
- Anglais
- Collection :
Caractéristiques
- EAN:
- 9783034807081
- Date de parution :
- 27-11-13
- Format:
- Livre relié
- Format numérique:
- Genaaid
- Dimensions :
- 160 mm x 234 mm
- Poids :
- 408 g
